Production (Stage)
Nika Pharmaceuticals, Inc.
NIKA
$0.6495
-$0.0004-0.06%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -71.96% | 71.23% | -16.83% | 97.84% | 134.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.96% | 71.23% | -16.83% | 97.84% | 134.69% |
| Operating Income | 71.96% | -71.23% | 16.83% | -97.12% | -134.69% |
| Income Before Tax | 71.96% | -71.23% | 16.83% | -97.12% | -134.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.96% | -71.23% | 16.83% | -97.12% | -134.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.96% | -71.23% | 16.83% | -97.12% | -134.69% |
| EBIT | 71.96% | -71.23% | 16.83% | -97.12% | -134.69% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 100.00% | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | 100.00% | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 17.15% | 17.70% | 16.26% | 16.26% | 0.00% |
| Average Diluted Shares Outstanding | 17.15% | 17.70% | 16.26% | 16.26% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |